Indoco Remedies Ltd 2019 AR2
The report highlights Indoco Remedies Ltd.'s financial and operational performance for the fiscal year 2018-2019. Key achievements include the withdrawal of the USFDA warning letter for Goa Plants II & III, and receiving UKMHRA approval for the new solid dosage facility in Baddi. The company also successfully commissioned its new API manufacturing facility at Patalganga. On the social front, the company engaged in various CSR initiatives under 'Sumati Sangopan,' focusing on education, preventive healthcare, and vocational skills.
Company: Indoco Remedies Ltd
Sector: Manufacturing
Country: India
Year: 2019
Type: AR2
Pages: 224
Back to company
Indoco Remedies Ltd
Annual Report
The report highlights Indoco Remedies Ltd.'s financial and operational performance for the fiscal year 2018-2019. Key achievements include the withdrawal of the USFDA warning letter for Goa Plants II & III, and receiving UKMHRA approval for the new solid dosage facility in Baddi. The company also successfully commissioned its new API manufacturing facility at Patalganga. On the social front, the company engaged in various CSR initiatives under 'Sumati Sangopan,' focusing on education, preventive healthcare, and vocational skills.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees